Medical-Glutathione™, A New Pharmaceutical, Can Safely Replete Intracellular Glutathione, Stem Vascular Oxidative Stress, Prevent NF-Kappa B Activation, and Bind To Cys215 of PTP 1B In Type 2 Diabetes (T2DM) Thereby Enabling Reduction of Insulin Resistanc

Program: Abstracts - Orals, Featured Poster Presentations, and Posters
Session: MON 842-862-Insulin Signaling & Action
Basic/Translational
Monday, June 17, 2013: 1:45 PM-3:45 PM
Expo Halls ABC (Moscone Center)

Poster Board MON-862
Harry Demopoulos*
Cell Redox Corporation, Elmsford, NY
Multiple processes participate in Diabetes and its Complications. Medical-Glutathione™ has properties that can safely serve synergistically with other modalities to maintain euglycemia, protect endothelium and vascular smooth muscle cells, suppress Free Radical Pathology, reduce Methyl Glyoxal, prevent activation of NF kappa B, and prevent formation of Plasminogen Activator Inhibitor (PAI), a prothrombotic product.  The problems with Glutathione as a Pharmaceutical include a high density of charges on the alpha carbon of glutamate, and the susceptibility of the free thiol to oxidation and desulferation into toxic Ophthalmic acid.

Crystalline Glutathione was formulated with Ascorbic Acid crystals into a Charge Transfer Complex by a series of timed mixing processes. This Complex proved to be charge neutral, with a more stable thiol group. Therefore, the two major impediments to the use of Glutathione as a drug were removed. Transport of glutathione is by ubiquitous transporters on plasma membranes, in mitochondrial membranes and in the nuclear envelope.  Our Medical-Glutathione™ speeds this transport.  

Medical-glutathione™ forms a Redox Couple in solution. In Phase 1, 2a Trials in Glutathione-deficient, early HIV-positive people it has proven to be safe, charge-neutral,  pure, stable, orally bioavailable with rapid absorption and intracellular distribution in timed blood samples of Peripheral Blood Mononuclear Cells (PBMC’s)starting at 30 minutes, peaking in the Area Under the Curve at 90 minutes with return to baseline at 120 minutes, followed by a second oral dose that approximately  repeats  the first dose AUC.

Oral repletion of intracellular glutathione is feasible and would serve to safely correct a number of the pathologic mechanisms in Diabetes, in concert with existing modalities.

Nothing to Disclose: HD

*Please take note of The Endocrine Society's News Embargo Policy at http://www.endo-society.org/endo2013/media.cfm

<< Previous Abstract | Next Abstract